Cassava Sciences (SAVA) said Monday that simufilam reduced seizure frequency in a mouse model of tuberous sclerosis complex-related epilepsy.
The company said the mice were treated with multiple doses of simufilam and seizure activity was monitored for three weeks.
According to the company, the drug candidate attenuated the progression of seizure activity with a statistically significant correlation between simufilam dose and the number of seizures.
A first clinical study is expected to begin in H1 2026, the company said.
Shares of Cassava Sciences rose more than 3% in recent premarket activity Monday.
Price: 2.20, Change: +0.08, Percent Change: +3.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。